Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
中文摘要

《亚洲男性学杂志》 2012; 14 (5): 726-731

《亚洲男性学杂志》 2012; 14 (5): 726-731

前列腺癌与MDM2 T309G多态性的风险、恶性程度、临床进展:一个多态性分析

Jie Yang, Wen Gao, Ning-Hong Song, Wei Wang, Jie-Xiu Zhang, Pei Lu, Li-Xin Hua and Min Gu (中国)

为探讨MDM2基因T309G多态性与前列腺癌(PCa)发病风险、恶性程度及临床进展间的关系,我们检索PubMed后,对全部7个已发表的相关研究进行了meta分析(共含5151个PCa病例和1003个对照)。在总体分析中,我们发现309G等位基因和低PCa发病风险显著相关(OR=0.85, 95% CI: 0.74-0.97),其中纯合子比较 GG vs. TT (OR=0.72, 95% CI: 0.55-0.95),优势遗传模型比较GT+GG vs. TT (OR=0.79, 95% CI: 0.65-0.96)。同时我们也发现309G等位基因也和更低肿瘤恶性度显著相关(OR=0.85, 95% CI: 0.75-0.96),其中杂合子比较GT vs. TT (OR=0.79, 95% CI: 0.65- 0.96),纯合子比较GG vs. TT (OR=0.76, 95% CI: 0.58-0.98),优势遗传模型比较GT+GG vs. TT (OR=0.81, 95% CI: 0.68-0.96)。此外,分层分析显示309G等位基因在高加索人群中和低PCa发病风险显著相关(OR=0.77, 95% CI: 0.61-0.96),其中纯合子比较GG vs. TT (OR=0.51, 95% CI: 0.31-0.86)。通过分层分析,我们也发现在所有遗传学模型中309G等位基因在高加索人群中和PCa更低恶性度及更慢临床进展显著相关。综上所述,通过meta分析我们发现在高加索人群中MDM2基因309G等位基因和低PCa发病率、更低恶性度及更慢临床进展显著相关,但在亚洲人群中尚未发现显著相关性。

关键词:临床进展,恶性程度,MDM2,萃取分析,多态性,前列腺癌,风险

此摘要文献来源:
Jie Yang, Wen Gao, Ning-Hong Song, Wei Wang, Jie-Xiu Zhang et al. The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis. Asian J Androl 2012; 14: 726-31.

 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.